Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chandra Bhagat PharmaBOM:542934 -1.11%65 EV-to-FCF is 4.81 as of Aug. 03, 2026, which is 41% below its 10-year median of 8.17. GuruFocus rates BOM:542934 with a GF Score™ of 65/100 and a GF Value™ of ₹70.16 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 72 Medical Distribution companies, Chandra Bhagat Pharma ranks better than 88.89% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Chandra Bhagat Pharma's Enterprise Value is ₹400 Mil.
Chandra Bhagat Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹83 Mil. Therefore, Chandra Bhagat Pharma's EV-to-FCF for today is 4.81.
The historical rank and industry rank for Chandra Bhagat Pharma's EV-to-FCF or its related term are showing as below:
BOM:542934'
s EV-to-FCF Range Over the Past 10 Years
Min: -9.43 Med: 8.17 Max: 26.05
Current: 4.31
During the past 10 years, the highest EV-to-FCF of Chandra Bhagat Pharma was 26.05. The lowest was -9.43. And the median was 8.17.
BOM:542934's EV-to-FCF is ranked better than 88.89% of 72
companies
in the Medical Distribution industry
Industry Median: 17.395
vs BOM:542934: 4.31
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chandra Bhagat Pharma's PE Ratio (TTM) for today is calculated as:
Chandra Bhagat Pharma's share price for today is ₹37.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chandra Bhagat Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Chandra Bhagat Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandra Bhagat Pharma EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Chandra Bhagat Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Chandra Bhagat Pharma's EV-to-FCF falls into.
Chandra Bhagat Pharma's current Enterprise Value is ₹400 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chandra Bhagat Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chandra Bhagat Pharma (BOM:542934) has a EV-to-FCF of 4.81 as of Aug. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Chandra Bhagat Pharma and its competitors. This is 41% below median its historical median of 8.17. According to the industry distribution chart, Chandra Bhagat Pharma ranks #8 out of 72 companies in the Medical Distribution industry, placing it in the top 11.1%.
Is Chandra Bhagat Pharma's EV-to-FCF too high?
Chandra Bhagat Pharma's current EV-to-FCF of 4.81 is 41% below median its 10-year median of 8.17. The Medical Distribution industry median EV-to-FCF is 17.40. Chandra Bhagat Pharma's value of 4.81 is 72.3% below this industry median. Based on the distribution chart, Chandra Bhagat Pharma ranks #8 out of 72 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Chandra Bhagat Pharma has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's EV-to-FCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Chandra Bhagat Pharma ranks #8 out of 72 companies for EV-to-FCF. This places Chandra Bhagat Pharma in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 17.40. Chandra Bhagat Pharma's value of 4.81 is 72.3% below this benchmark. While the company's 10-year median is 8.17 vs. the industry median of 17.40, Chandra Bhagat Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 17.40, based on 72 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chandra Bhagat Pharma's current EV-to-FCF of 4.81 is 72.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Chandra Bhagat Pharma and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 17.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chandra Bhagat Pharma's current EV-to-FCF is 4.81, which is 41% below median its own 10-year median of 8.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Possible Value Trap. The stock's GF Value™ is ₹70.16, compared to a current price of ₹37.50 — trading 46.6% below its estimated fair value. The current EV-to-FCF is 4.81, which is 41% below median its 10-year median of 8.17 and 72.3% below the Medical Distribution industry median of 17.40. Chandra Bhagat Pharma's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current EV-to-FCF is 4.81 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?
Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued.
The current stock price of ₹37.50 is trading 46.6% below its estimated GF Value™ of ₹70.16.
GuruFocus considers Chandra Bhagat Pharma to be Possible Value Trap.
Key valuation signals for BOM:542934:
EV-to-FCF: 4.81 (41% below median its 10-year median of 8.17)
GF Value™: ₹70.16 vs. price of ₹37.50 (46.6% below fair value)
Industry Position: 72.3% below the Medical Distribution median (#8 of 72)
No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
65GF Score
Get the complete analysis for BOM:542934
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542934 has been successfully added to your 
